IMCR Immunocore
- 47.996
- -2.474-4.90%
Immunocore News
Analysts Offer Insights on Healthcare Companies: Cresco Labs (OtherCRLBF) and Immunocore Holdings (IMCR)
Optimistic Buy Rating for Immunocore Holdings Amid Promising Brenetafusp Study and Strategic Developments
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Immunocore Holdings (IMCR) and Madrigal Pharmaceuticals (MDGL)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Immunocore Holdings Is Maintained at Buy by Mizuho
Immunocore Holdings Is Maintained at Buy by Mizuho
Mizuho Maintains Buy on Immunocore Hldgs, Lowers Price Target to $88
Mizuho analyst Graig Suvannavejh maintains Immunocore Hldgs with a Buy and lowers the price target from $90 to $88.
Immunocore Holdings Plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Last week, you might have seen that Immunocore Holdings plc (NASDAQ:IMCR) released its quarterly result to the market. The early response was not positive, with shares down 2.1% to US$58.95 in the pas
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Immunocore Holdings Price Target Raised to $67.00/Share From $63.00 by Canaccord Genuity
Immunocore Holdings Price Target Raised to $67.00/Share From $63.00 by Canaccord Genuity
Immunocore Holdings Is Maintained at Buy by HC Wainwright & Co.
Immunocore Holdings Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : Maintaining the Immunocore Hldgs (IMCR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $90.00 to $100.00.
HC Wainwright & Co. : Maintaining the Immunocore Hldgs (IMCR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $90.00 to $100.00.
HC Wainwright & Co. Maintains Buy on Immunocore Hldgs, Raises Price Target to $100
HC Wainwright & Co. analyst Patrick Trucchio maintains Immunocore Hldgs (NASDAQ:IMCR) with a Buy and raises the price target from $90 to $100.
Buy Rating Affirmed for Immunocore Holdings on Strong KIMMTRAK Sales and Promising Pipeline Growth
Needham: Reiterates Immunocore Hldgs (IMCR.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham: Reiterates Immunocore Hldgs (IMCR.US) rating and adjusted from buy to buy rating, target price is $81.00.
Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Needham analyst Gil Blum reiterates Immunocore Hldgs with a Buy and maintains $81 price target.
Barclays Remains a Buy on Immunocore Holdings (IMCR)
Buy Rating for Immunocore Holdings on Strong Financials and Expanding Innovative Pipeline
Immunocore Holdings Outperforms With Kimmtrak Sales Surpassing Estimates; Maintains Buy Rating
Immunocore Hldgs (IMCR.US): The 2024 Q1 financial report achieved revenue of US$70.502 million, with a previous value of US$50.93 million, with an expected value of US$71.15 million; earnings per share were -0.49 dollars, previous value of -0.43 dollars,
Immunocore Hldgs (IMCR.US): The 2024 Q1 financial report achieved revenue of US$70.502 million, with a previous value of US$50.93 million, with an expected value of US$71.15 million; earnings per share were -0.49 dollars, previous value of -0.43 dollars, and expected value of -0.36 dollars.
Analysis
Price Target
No Data
